No black box warning on record for Ezetimibe And Simvastatin

As of the latest FDA labeling reviewed, Ezetimibe And Simvastatin (EZETIMIBE AND SIMVASTATIN) does not carry a black box warning. Standard warnings and precautions still apply — see the full Ezetimibe And Simvastatin medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Patients should be advised of the increased risk of myopathy, including rhabdomyolysis, with the 10 mg/80 mg dose. ( 5.1 ) Patients should be advised to report promptly any unexplained and/or persistent muscle pain, tenderness, or weakness. Ezetimibe and simvastatin tablets should be discontinued immediately if myopathy is diagnosed or suspected. ( 5.1 ). Skeletal muscle

No black box warning on record for Ezetimibe And Simvastatin

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Patients should be advised of the increased risk of myopathy, including rhabdomyolysis, with the 10 mg/80 mg dose. ( 5.1 ) Patients should be advised to report promptly any unexplained and/or persistent muscle pain, tenderness, or weakness. Ezetimibe and simvastatin tablets should be discontinued immediately if myopathy is diagnosed or suspected. ( 5.1 ). Skeletal muscle

Ezetimibe And Simvastatin Black Box Warning

No black box warning on record for Ezetimibe And Simvastatin

Other warnings & precautions

Ezetimibe And Simvastatin Black Box Warning

No black box warning on record for Ezetimibe And Simvastatin

Other warnings & precautions